Condition: Acute Leukemia · Severe Aplastic Anemia · Non-hodgkin Lymphoma · Sponsor: Mitchell Cairo
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
This description comes directly from the study's public registry record.
Mitchell S Cairo, MD · 9145942150 · mitchell_cairo@nymc.edu
Lauren Harrison, RN · 6172857844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| New York Medical College | Valhalla, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04099966